검색
Karyopharm Therapeutics Inc
KPTI관심 목록에 추가
0.832USD
+0.352+73.33%
종가 10-28 16:00（ET）
18.87M시가총액
손실P/E TTM
장외 거래 19:59 (ET)0.800USD-0.031-3.73%
장외 거래 19:59 (ET)Karyopharm Therapeutics Inc 정보 회사
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc 프로필
종목 코드 KPTI
회사 이름Karyopharm Therapeutics Inc
상장일Nov 06, 2013
CEOPaulson (Richard A)
직원 수279
유형Ordinary Share
회계 연도 종료Nov 06
주소85 Wells Avenue
도시NEWTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02459
전화16176580600
웹사이트https://karyopharm.com/
종목 코드 KPTI
상장일Nov 06, 2013
CEOPaulson (Richard A)
Karyopharm Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
자주 묻는 질문
Karyopharm Therapeutics Inc의 상위 5대 주주는 누구인가요?
Karyopharm Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Michael Mano, J.D.
Karyopharm Therapeutics Inc(KPTI)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Karyopharm Therapeutics Inc의 주식을 보유한 기관은 총 236곳이며, 이들이 보유한 주식의 총 가치는 약 14.10M로 전체 발행 주식의 62.56%를 차지합니다. 이는 2025Q4 대비 5055019.00 증가한 수치입니다.